Guggenheim initiated coverage of Exact Sciences with a Buy rating and $90 price target. The analyst initiated coverage on nine select specialty tools and specialty diagnostic lab companies. The life sciences tools group remains a large and growing industry where innovation expands applications and opens up new markets, the analyst tells investors in a research note. The firm says that over time, these applications can enable the development of disruptive therapies. Guggenheim’s top picks are Illumina (ILMN), Natera (NTRA) and Exact Sciences (EXAS).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EXAS:
- Exact Sciences initiated with bullish view at Wolfe Research, here’s why
- Exact Sciences initiated with bullish view at Wolfe Research
- Exact Sciences has work to do, says UBS
- Exact Sciences files patent infringement lawsuit against Geneoscopy
- Exact Sciences price target lowered to $88 from $106 at Craig-Hallum